Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2004 Oct;80(948):577–580. doi: 10.1136/pgmj.2003.017467

Justified and unjustified use of growth hormone

A J van der Lely
PMCID: PMC1743118  PMID: 15466991

Abstract

Growth hormone (GH) replacement therapy for children and adults with proven GH deficiency due to a pituitary disorder has become an accepted therapy with proven efficacy. GH is increasingly suggested, however, as a potential treatment for frailty, osteoporosis, morbid obesity, cardiac failure, and various catabolic conditions. However, the available placebo controlled studies have not reported many significant beneficial effects, and it might even be dangerous to use excessive GH dosages in conditions in which the body has just decided to decrease GH actions. GH can indeed induce changes in body composition that are considered to be advantageous to GH deficient and non-GH deficient subjects. In contrast to GH replacement therapy in GH deficient subjects, however, excessive GH action due to GH misuse seems to be ineffective in improving muscle power. Moreover, there are no available study data to indicate that the use of GH for non-GH deficient subjects should be advocated, especially as animal data suggest that lower GH levels are positively correlated with longevity.

Full Text

The Full Text of this article is available as a PDF (201.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abs R., Bengtsson B. A., Hernberg-Stâhl E., Monson J. P., Tauber J. P., Wilton P., Wüster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 1999 Jun;50(6):703–713. doi: 10.1046/j.1365-2265.1999.00695.x. [DOI] [PubMed] [Google Scholar]
  2. Armanini D., Faggian D., Scaroni C., Plebani M. Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. Br J Sports Med. 2002 Apr;36(2):148–149. doi: 10.1136/bjsm.36.2.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry M. C., Mealy K., Sheehan S. J., Burke P. E., Cunningham A. J., Leahy A., Bouchier Hayes D. The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg. 1998 Oct;16(4):311–319. doi: 10.1016/s1078-5884(98)80050-6. [DOI] [PubMed] [Google Scholar]
  4. Bartke A., Coschigano K., Kopchick J., Chandrashekar V., Mattison J., Kinney B., Hauck S. Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol A Biol Sci Med Sci. 2001 Aug;56(8):B340–B349. doi: 10.1093/gerona/56.8.b340. [DOI] [PubMed] [Google Scholar]
  5. Barzilai N., Shuldiner A. R. Searching for human longevity genes: the future history of gerontology in the post-genomic era. J Gerontol A Biol Sci Med Sci. 2001 Feb;56(2):M83–M87. doi: 10.1093/gerona/56.2.m83. [DOI] [PubMed] [Google Scholar]
  6. Bengtsson B. A., Abs R., Bennmarker H., Monson J. P., Feldt-Rasmussen U., Hernberg-Stahl E., Westberg B., Wilton P., Wüster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab. 1999 Nov;84(11):3929–3935. doi: 10.1210/jcem.84.11.6088. [DOI] [PubMed] [Google Scholar]
  7. Bowers Larry D. Abuse of performance-enhancing drugs in sport. Ther Drug Monit. 2002 Feb;24(1):178–181. doi: 10.1097/00007691-200202000-00028. [DOI] [PubMed] [Google Scholar]
  8. Butterfield G. E., Thompson J., Rennie M. J., Marcus R., Hintz R. L., Hoffman A. R. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol. 1997 Jan;272(1 Pt 1):E94–E99. doi: 10.1152/ajpendo.1997.272.1.E94. [DOI] [PubMed] [Google Scholar]
  9. Carter Christy S., Ramsey Melinda M., Ingram Rhonda L., Cashion Adrienne B., Cefalu William T., Wang Z. Q., Sonntag William E. Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination. J Gerontol A Biol Sci Med Sci. 2002 May;57(5):B177–B188. doi: 10.1093/gerona/57.5.b177. [DOI] [PubMed] [Google Scholar]
  10. Cassel C. K. Successful aging. How increased life expectancy and medical advances are changing geriatric care. Geriatrics. 2001 Jan;56(1):35–40. [PubMed] [Google Scholar]
  11. Chan J. M., Stampfer M. J., Giovannucci E., Gann P. H., Ma J., Wilkinson P., Hennekens C. H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998 Jan 23;279(5350):563–566. doi: 10.1126/science.279.5350.563. [DOI] [PubMed] [Google Scholar]
  12. Chipman J. J., Attanasio A. F., Birkett M. A., Bates P. C., Webb S., Lamberts S. W. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997 Apr;46(4):473–481. doi: 10.1046/j.1365-2265.1997.1660984.x. [DOI] [PubMed] [Google Scholar]
  13. Colao Annamaria, di Somma Carolina, Pivonello Rosario, Cuocolo Alberto, Spinelli Letizia, Bonaduce Domenico, Salvatore Marco, Lombardi Gaetano. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab. 2002 Mar;87(3):1088–1093. doi: 10.1210/jcem.87.3.8336. [DOI] [PubMed] [Google Scholar]
  14. Congeni Joseph, Miller Stephen. Supplements and drugs used to enhance athletic performance. Pediatr Clin North Am. 2002 Apr;49(2):435–461. doi: 10.1016/s0031-3955(01)00013-x. [DOI] [PubMed] [Google Scholar]
  15. Coschigano K. T., Clemmons D., Bellush L. L., Kopchick J. J. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology. 2000 Jul;141(7):2608–2613. doi: 10.1210/endo.141.7.7586. [DOI] [PubMed] [Google Scholar]
  16. Cuttica C. M., Castoldi L., Gorrini G. P., Peluffo F., Delitala G., Filippa P., Fanciulli G., Giusti M. Effects of six-month administration of recombinant human growth hormone to healthy elderly subjects. Aging (Milano) 1997 Jun;9(3):193–197. doi: 10.1007/BF03340149. [DOI] [PubMed] [Google Scholar]
  17. Deijen J. B., van der Veen E. A. The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. J Endocrinol Invest. 1999;22(5 Suppl):127–136. [PubMed] [Google Scholar]
  18. Fine R. N., Sullivan E. K., Tejani A. The impact of recombinant human growth hormone treatment on final adult height. Pediatr Nephrol. 2000 Jul;14(7):679–681. doi: 10.1007/s004670000383. [DOI] [PubMed] [Google Scholar]
  19. Frederiksen Henrik, McGue Matt, Jeune Bernard, Gaist David, Nybo Hanne, Skytthe Axel, Vaupel James W., Christensen Kaare. Do children of long-lived parents age more successfully? Epidemiology. 2002 May;13(3):334–339. doi: 10.1097/00001648-200205000-00015. [DOI] [PubMed] [Google Scholar]
  20. Frindik J. P., Baptista J. Adult height in growth hormone deficiency: historical perspective and examples from the national cooperative growth study. Pediatrics. 1999 Oct;104(4 Pt 2):1000–1004. [PubMed] [Google Scholar]
  21. Frisch H. Growth hormone and body composition in athletes. J Endocrinol Invest. 1999;22(5 Suppl):106–109. [PubMed] [Google Scholar]
  22. Han Y. M., Kim J. K., Roh B. S., Song H. Y., Lee J. M., Lee Y. H., Lee S. Y., Chung G. H., Kim C. S., Sohn M. H. Renal angiomyolipoma: selective arterial embolization--effectiveness and changes in angiomyogenic components in long-term follow-up. Radiology. 1997 Jul;204(1):65–70. doi: 10.1148/radiology.204.1.9205224. [DOI] [PubMed] [Google Scholar]
  23. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998 May 9;351(9113):1393–1396. doi: 10.1016/S0140-6736(97)10384-1. [DOI] [PubMed] [Google Scholar]
  24. Herschbach P., Henrich G., Strasburger C. J., Feldmeier H., Marín F., Attanasio A. M., Blum W. F. Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency. Eur J Endocrinol. 2001 Sep;145(3):255–265. doi: 10.1530/eje.0.1450255. [DOI] [PubMed] [Google Scholar]
  25. Hulthén L., Bengtsson B. A., Sunnerhagen K. S., Hallberg L., Grimby G., Johannsson G. GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab. 2001 Oct;86(10):4765–4770. doi: 10.1210/jcem.86.10.7897. [DOI] [PubMed] [Google Scholar]
  26. Janssen F., Van Damme-Lombaerts R., Van Dyck M., Hall M., Schurmans T., Herman J., Hooghe L., Van Damme B. Impact of growth hormone treatment on a Belgian population of short children with renal allografts. Pediatr Transplant. 1997 Nov;1(2):190–196. [PubMed] [Google Scholar]
  27. Janssen Y. J., Doornbos J., Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab. 1999 Jan;84(1):279–284. doi: 10.1210/jcem.84.1.5411. [DOI] [PubMed] [Google Scholar]
  28. Janssens H., Vanderschueren D. M. Endocrinological aspects of aging in men: is hormone replacement of benefit? Eur J Obstet Gynecol Reprod Biol. 2000 Sep;92(1):7–12. doi: 10.1016/s0301-2115(00)00420-6. [DOI] [PubMed] [Google Scholar]
  29. Johannsson G., Bengtsson B. A., Ahlmén J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis. 1999 Apr;33(4):709–717. doi: 10.1016/s0272-6386(99)70223-4. [DOI] [PubMed] [Google Scholar]
  30. Johannsson G., Svensson J., Bengtsson B. A. Growth hormone and ageing. Growth Horm IGF Res. 2000 Apr;10 (Suppl B):S25–S30. doi: 10.1016/s1096-6374(00)80006-4. [DOI] [PubMed] [Google Scholar]
  31. Johansson S. Longevity in women. Cardiovasc Clin. 1989;19(3):3–16. [PubMed] [Google Scholar]
  32. Jørgensen J. O., Vahl N., Hansen T. B., Thuesen L., Hagen C., Christiansen J. S. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 1996 Dec;45(6):681–688. doi: 10.1046/j.1365-2265.1996.8720883.x. [DOI] [PubMed] [Google Scholar]
  33. Kalu D. N., Orhii P. B., Chen C., Lee D. Y., Hubbard G. B., Lee S., Olatunji-Bello Y. Aged-rodent models of long-term growth hormone therapy: lack of deleterious effect on longevity. J Gerontol A Biol Sci Med Sci. 1998 Nov;53(6):B452–B463. doi: 10.1093/gerona/53a.6.b452. [DOI] [PubMed] [Google Scholar]
  34. Kattar M. M., Grignon D. J., Eble J. N., Hurley P. M., Lewis P. E., Sakr W. E., Cher M. L. Chromosomal analysis of renal angiomyolipoma by comparative genomic hybridization: evidence for clonal origin. Hum Pathol. 1999 Mar;30(3):295–299. doi: 10.1016/s0046-8177(99)90008-4. [DOI] [PubMed] [Google Scholar]
  35. Kehely Anne, Bates Peter C., Frewer Paul, Birkett Martin, Blum Werner F., Mamessier Pascale, Ezzat Shereen, Ho Ken K. Y., Lombardi Gaetano, Luger Anton. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab. 2002 May;87(5):1974–1979. doi: 10.1210/jcem.87.5.8454. [DOI] [PubMed] [Google Scholar]
  36. Kissmeyer-Nielsen P., Jensen M. B., Laurberg S. Perioperative growth hormone treatment and functional outcome after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg. 1999 Feb;229(2):298–302. doi: 10.1097/00000658-199902000-00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lange K. H., Isaksson F., Juul A., Rasmussen M. H., Bülow J., Kjaer M. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab. 2000 Nov;279(5):E989–E996. doi: 10.1152/ajpendo.2000.279.5.E989. [DOI] [PubMed] [Google Scholar]
  38. Ma J., Pollak M. N., Giovannucci E., Chan J. M., Tao Y., Hennekens C. H., Stampfer M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 1999 Apr 7;91(7):620–625. doi: 10.1093/jnci/91.7.620. [DOI] [PubMed] [Google Scholar]
  39. Macintyre J. G. Growth hormone and athletes. Sports Med. 1987 Mar-Apr;4(2):129–142. doi: 10.2165/00007256-198704020-00004. [DOI] [PubMed] [Google Scholar]
  40. Promislow D. E. On size and survival: progress and pitfalls in the allometry of life span. J Gerontol. 1993 Jul;48(4):B115–B123. doi: 10.1093/geronj/48.4.b115. [DOI] [PubMed] [Google Scholar]
  41. Ramaswami U., Hindmarsh P. C., Brook C. G. Growth hormone therapy in hypochondroplasia. Acta Paediatr Suppl. 1999 Feb;88(428):116–117. doi: 10.1111/j.1651-2227.1999.tb14368.x. [DOI] [PubMed] [Google Scholar]
  42. Rose M. R. Can human aging be postponed? Sci Am. 1999 Dec;281(6):106–111. doi: 10.1038/scientificamerican1299-106. [DOI] [PubMed] [Google Scholar]
  43. Rosén T., Bengtsson B. A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990 Aug 4;336(8710):285–288. doi: 10.1016/0140-6736(90)91812-o. [DOI] [PubMed] [Google Scholar]
  44. Rudman D., Feller A. G., Nagraj H. S., Gergans G. A., Lalitha P. Y., Goldberg A. F., Schlenker R. A., Cohn L., Rudman I. W., Mattson D. E. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990 Jul 5;323(1):1–6. doi: 10.1056/NEJM199007053230101. [DOI] [PubMed] [Google Scholar]
  45. Samaras T. T., Elrick H., Storms L. H. Height, health and growth hormone. Acta Paediatr. 1999 Jun;88(6):602–609. doi: 10.1080/08035259950169233. [DOI] [PubMed] [Google Scholar]
  46. Samaras T. T., Storms L. H. Impact of height and weight on life span. Bull World Health Organ. 1992;70(2):259–267. [PMC free article] [PubMed] [Google Scholar]
  47. Sas T. C., de Muinck Keizer-Schrama S. M., Stijnen T., van Teunenbroek A., Hokken-Koelega A. C., Waelkens J. J., Massa G. G., Vulsma T., Gerver W. J., Reeser H. M. Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone. Arch Dis Child. 1999 Jan;80(1):36–41. doi: 10.1136/adc.80.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Savine R., Sönksen P. H. Is the somatopause an indication for growth hormone replacement? J Endocrinol Invest. 1999;22(5 Suppl):142–149. [PubMed] [Google Scholar]
  49. Schambelan M., Mulligan K., Grunfeld C., Daar E. S., LaMarca A., Kotler D. P., Wang J., Bozzette S. A., Breitmeyer J. B. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med. 1996 Dec 1;125(11):873–882. doi: 10.7326/0003-4819-125-11-199612010-00002. [DOI] [PubMed] [Google Scholar]
  50. Simon D., Touati G., Prieur A. M., Ruiz J. C., Czernichow P. Growth hormone treatment of short stature and metabolic dysfunction in juvenile chronic arthritis. Acta Paediatr Suppl. 1999 Feb;88(428):100–105. doi: 10.1111/j.1651-2227.1999.tb14363.x. [DOI] [PubMed] [Google Scholar]
  51. Simopoulos A. P., Van Itallie T. B. Body weight, health, and longevity. Ann Intern Med. 1984 Feb;100(2):285–295. doi: 10.7326/0003-4819-100-2-285. [DOI] [PubMed] [Google Scholar]
  52. Steiner M. S., Goldman S. M., Fishman E. K., Marshall F. F. The natural history of renal angiomyolipoma. J Urol. 1993 Dec;150(6):1782–1786. doi: 10.1016/s0022-5347(17)35895-0. [DOI] [PubMed] [Google Scholar]
  53. Svensson J., Johannsson G., Bengtsson B. A. Body composition and quality of life as markers of the efficacy of growth hormone replacement therapy in adults. Horm Res. 2001;55 (Suppl 2):55–60. doi: 10.1159/000063476. [DOI] [PubMed] [Google Scholar]
  54. Swerdlow A. J., Higgins C. D., Adlard P., Preece M. A. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet. 2002 Jul 27;360(9329):273–277. doi: 10.1016/s0140-6736(02)09519-3. [DOI] [PubMed] [Google Scholar]
  55. Taira Kazuhiko, Tanaka Hideki, Arakawa Masashi, Nagahama Naoki, Uza Miyoko, Shirakawa Shuichiro. Sleep health and lifestyle of elderly people in Ogimi, a village of longevity. Psychiatry Clin Neurosci. 2002 Jun;56(3):243–244. doi: 10.1046/j.1440-1819.2002.01014.x. [DOI] [PubMed] [Google Scholar]
  56. Takala J., Ruokonen E., Webster N. R., Nielsen M. S., Zandstra D. F., Vundelinckx G., Hinds C. J. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999 Sep 9;341(11):785–792. doi: 10.1056/NEJM199909093411102. [DOI] [PubMed] [Google Scholar]
  57. Van der Lely A. J., Lamberts S. W., Jauch K. W., Swierstra B. A., Hertlein H., Danielle De Vries D., Birkett M. A., Bates P. C., Blum W. F., Attanasio A. F. Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol. 2000 Nov;143(5):585–592. doi: 10.1530/eje.0.1430585. [DOI] [PubMed] [Google Scholar]
  58. Wu Z., Bidlingmaier M., Dall R., Strasburger C. J. Detection of doping with human growth hormone. Lancet. 1999 Mar 13;353(9156):895–895. doi: 10.1016/S0140-6736(99)00775-8. [DOI] [PubMed] [Google Scholar]
  59. von Werder K. The somatopause is no indication for growth hormone therapy. J Endocrinol Invest. 1999;22(5 Suppl):137–141. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES